Table II.
Percent Body Weight Change Following Treatment with the Combination Therapy
| Tumor type | Treatment | Body weight change (% change from initial) | |||
|---|---|---|---|---|---|
| Day 7 | Day 14 | Day 21 | Day 28 | ||
| SKOV3TR | Control | 103 ± 1 | 105 ± 2 | 108 ± 2 | 106 ± 2 |
| PTX (S) | 103 ± 2 | 102 ± 2 | 104 ± 2 | 103 ± 3 | |
| PTX (NP) | 110 ± 8 | 112 ± 8 | 113 ± 7 | 113 ± 8 | |
| PTX + CER (S) | 100 ± 3 | 100 ± 3 | 98.5 ± 4.4 | 99.8 ± 3.0 | |
| PTX + CER (NP) | 101 ± 1 | 104 ± 2 | 106 ± 1 | 107 ± 2 | |
| MCF7TR | Control | 95.2 ± 2.1 | 95.2 ± 6.7 | 95.2 ± 7.4 | 102 ± 3 |
| PTX (S) | 98.1 ± 3.3 | 95.3 ± 4.9 | 94.4 ± 5.2 | 89.9 ± 6.0 | |
| PTX (NP) | 101 ± 0.4 | 102 ± 1 | 102 ± 2 | 93.0 ± 9.9 | |
| PTX + CER (S) | 97.6 ± 3.5 | 90.7 ± 3.5 | 85.2 ± 3.5 | 97.8 ± 3.5 | |
| PTX + CER (NP) | 101 ± 2 | 98.7 ± 2.7 | 97.1 ± 4.3 | 101 ± 1 | |
Average percent change in body weight over week 1 through week 4 after treatment with 20 mg/kg PTX and/or 80 mg/kg CER in solution or in polymer-blend nanoparticles as a measure of toxicity in mice bearing SKOV3TR ovarian adenocarcinoma and MCF7TR breast adenocarcinoma tumors. Control indicates no treatment. (n = 4 mice per treatment per tumor type)
PTX paclitaxel, CER C6-ceramide, S solution, NP nanoparticles